Evidence map›Paper›PMID 37608645›Full record

ArticleHIV research & clinical practice2023

Increasing the meaningful involvement of women in HIV cure-related research: a qualitative interview study in the United States.

Karine Dubé, Elizabeth Barr, Morgan Philbin, Amaya Perez-Brumer, Brian Minalga, Beth Peterson, Dawn Averitt, Bridgette Picou, Krista Martel, Cecilia Chung and 12 more

Abstract read
In one paragraph

Article in HIV research & clinical practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Trial
  2. The HIV Reservoir and Immune Landscape Across the Life Course of Women: Implications for Cure Strategies.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Karine DubéSchool of Medicine, Division of Infectious Diseases and Global Public Health (IDGPH), University of California San Diego (UCSD), San Diego, CA, USA.ORCID 0000-0003-3458-1539
Elizabeth BarrNational Institutes of Health (NIH) Office of Research on Women's Health (ORWH), Bethesda, MD, USA.
Morgan PhilbinCenter for Vulnerable Populations, Department of Medicine, University of California San Francisco (UCSF), San Francisco, CA, USA.
Amaya Perez-BrumerDalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Brian MinalgaFred Hutchinson Cancer Center, Office of HIV/AIDS Network Coordination (HANC), Seattle, WA, USA.
Beth PetersonWistar Institute and BEAT-HIV Delaney Collaboratory Towards an HIV-1 Cure, Philadelphia, PA, USA.
Dawn AverittThe Well Project and Women's Research Initiative on HIV/AIDS (WRI), Nationwide, OH, USA.
Bridgette PicouThe Well Project and Women's Research Initiative on HIV/AIDS (WRI), Nationwide, OH, USA.
Krista MartelThe Well Project and Women's Research Initiative on HIV/AIDS (WRI), Nationwide, OH, USA.
Cecilia ChungTransgender Law Center, Oakland, CA, USA.
María MejíaThe Well Project Community Advisory Board (CAB), Nationwide, OH, USA.
Martha CameronInternational Community of Women Living with HIV (ICW), North America.
Gail GrahamUniversity of Maryland PATIENTS Program, Maryland, MD, USA.
Lynda DeeAIDS Action Baltimore, Baltimore, MD, USA.
Dázon Dixon DialloSisterLove, Inc., Atlanta, GA, USA.
Ebony GordonDelaney AIDS Research Enterprise (DARE) Community Advisory Board, San Francisco, CA, USA.
Anastasia KorolkovaSchool of Medicine, Division of Infectious Diseases and Global Public Health (IDGPH), University of California San Diego (UCSD), San Diego, CA, USA.
Typhanye DyerSchool of Public Health, University of Maryland, College Park, MD, USA.
Judith D AuerbachDivision of Prevention Science, Department of Medicine, UCSF, San Francisco, CA, USA.
Eileen ScullyJohns Hopkins School of Medicine, Baltimore, MD, 21205, USA.
Krista L DongHarvard Medical School, Boston, MA, USA.
Sara GianellaSchool of Medicine, Division of Infectious Diseases and Global Public Health (IDGPH), University of California San Diego (UCSD), San Diego, CA, USA.

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7M
HOPE - HIV Obstruction by Programmed EpigeneticsUM1AI164559 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI Lishomwa C Ndhlovu, Melanie Maria Ott · 2021 to 2026
$32.2M
First-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5M
Training Program for Scientists Conducting Research to Reduce HIV Health DisparitR25MH067127 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Emily A Arnold, Torsten Brian Neilands · 2003 to 2026
$5.4M
Investigating Psychosocial Experiences of HIV Cure Trial Participants Undergoing Extended HIV Treatment Interruptions: Implications for Ethical ConductR01MH126768 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DUBE, KARINE, SAUCEDA, JOHN ANDREW · 2021 to 2025
$3.6M
Optimizing HIV adherence by developing a shared decision support tool to facilitate women's choice between oral and LAI ARTR34MH124552 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHILBIN, MORGAN MARI · 2021 to 2023
$773k
Pilot Integration of Participant-Centered Outcomes in HIV Cure Research in the United States: Implications for Ethical ConductR21MH118120 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUBE, KARINE · 2019 to 2020
$566k
Integrating Trauma-Informed Research in Assessment of Young Women Engaged in HIV Cure Research (Post-Intervention Control) Trial with Analytical Treatment Interruption in Durban, South AfricaR21MH132406 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DUBE, KARINE · 2023 to 2023
$422k
NCATS NIH HHS UL1 TR001442NIAID NIH HHS P30 AI036214NIAID NIH HHS UM1 AI126620NIAID NIH HHS UM1 AI164559NIAID NIH HHS UM1 AI164570NIMH NIH HHS P30 MH062246NIMH NIH HHS R01 MH126768NIMH NIH HHS R21 MH118120NIMH NIH HHS R21 MH132406NIMH NIH HHS R25 MH067127NIMH NIH HHS R34 MH124552
6 · The paper itself

Abstract

backgroundCisgender women represent over half of people living with HIV globally. However, current research efforts toward a cure for HIV focus predominantly on cisgender men. The under-representation of women in HIV cure clinical studies is particularly problematic given data suggesting that sex-dependent phenotypes limit scientific discovery.

objectiveWe aimed to generate considerations to increase the meaningful involvement of women in HIV cure-related research. MATERIALS AND

methodsWe conducted in-depth interviews with biomedical researchers and community members to better understand factors that could increase the meaningful involvement of women in HIV cure clinical trials. Participants were affiliated with academia, industry, community advisory boards, and community-based organizations, and were identified using listings from the AIDS Clinical Trials Group and the Martin Delaney Collaboratories. We used conventional content analysis to analyze the qualitative data.

resultsWe recruited 27 participants, of whom 11 were biomedical researchers and 16 were community members. Participants included 25 cisgender women, 1 transgender woman, and 1 cisgender man. Key considerations emerged, including the need to ensure that HIV cure studies reflect HIV epidemiologic trends and having accurate representation by sex and gender in HIV cure research. To increase the meaningful involvement of women, recommendations included instituting intentional enrollment goals, frequent and mandatory reporting on enrollment, and incentives for sites to enroll women. Additional themes included the need for agency and self-determination, attention to lived experiences, trauma and healing, and adequate support for women (e.g. logistical, psychosocial, mental, emotional, and physical). Participants noted that women would be willing to participate in HIV cure trials, related procedures (e.g. biopsies), and analytical treatment interruptions. They also expressed a desired for women-centered and holistic clinical trial designs that account for intersectionality.

conclusionsOur empirical inquiry extends recent calls to action to increase diversity of people involved in HIV cure research. Redressing the under-inclusion of women in HIV cure research is an urgent imperative. The entire field must mobilize and reform to achieve this goal. Meaningfully involving women across the gender spectrum in HIV cure research is needed to ensure that interventions are safe, effective, scalable, and acceptable for all people with HIV.

Indexed as

Academies and InstitutesHIV InfectionsBiopsyEmpirical ResearchFemaleHumansMaleQualitative ResearchUnited Statesclinical trialsHIVHIV cure researchmeaningful involvementparticipationWomen

Identifiers

PMID37608645
PMCPMC10454980

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.